EGFR and HER-2 expression by immunohistochemistry (IHC) and their mRNA by <i>in situ</i> hybridization (ISH) in canine mammary carcinomas in mixed tumors and carcinosarcomas.

<p>EGFR and HER-2 expression by immunohistochemistry (IHC) and their mRNA by <i>in situ</i> hybridization (ISH) in canine mammary carcinomas in mixed tumors and carcinosarcomas.</p

Clinicopathological characteristics of canine mammary carcinomas in mixed tumors (CMTs) and carcinosarcomas (CSs).

<p>Clinicopathological characteristics of canine mammary carcinomas in mixed tumors (CMTs) and carcinosarcomas (CSs).</p

<i>HER-2</i> and <i>EGFR</i> mRNA Expression and Its Relationship with Versican in Malignant Matrix-Producing Tumors of the Canine Mammary Gland - Fig 2

<p>(A)(B) <i>EGFR</i> and (C)(D) <i>HER-2</i> mRNA expression in canine mammary tumours. Difference between <i>in situ</i> (IS) and invasive (IN) areas in versican low (G1) and high (G2) expression groups. Wilcoxon test. *p<0.05 ***p<0.001.</p

Differences versican expression in <i>in situ</i> (IS) and invasive (IN) carcinomatous areas in versican low (G1) and high (G2) expression groups in canine mammary tumours.

<p>Wilcoxon test.</p

RNA-ISH analysis of <i>EGFR</i> gene expression in canine mammary tumours showing cytoplasmatic dots.

<p>(A) <i>In situ</i> carcinomatous areas showing RNA ISH score 3: in carcinomas in mixed tumours. (B) Invasive carcinomatous areas showing RNA ISH score 0 in carcinomas in mixed tumours (dots indicated by red arrow). (C) <i>In situ</i> carcinomatous areas showing RNA ISH score 2 in carcinosarcoma. (D) Invasive carcinomatous areas showing RNA ISH score 1 in carcinosarcoma (magnification x60).</p